Delgocitinib for chronic hand eczema in adolescents

Delgocitinib is currently in clinical development for the treatment of adolescents (aged 12-17 years) with moderate to severe chronic hand eczema (CHE). Hand eczema is one of the most common types of eczema. It mainly affects the palms but can also affect other parts of the hand. CHE is hand eczema that lasts for more than 3 months or relapses at least twice within a year. It is characterised by dry, itchy, and painful skin that is red or darker than the surrounding skin. In severe cases, the hands can become very painful, making it difficult to carry out day-to-day tasks. CHE is a significant burden and is particularly common in young women or those working in high-risk industries such as healthcare or manufacturing.